CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL

Guest: Ryan Quigley <br> <article data-scroll-anchor="false" data-testid="conversation-turn-2" data-turn="assistant" data-turn-id="request-WEB:2bf976f8-39e9-4023-83be-802cf688453c-0" dir="auto" tabindex="-1"> <div tabindex="-1"> <div data-message-author-role="assistant" data-message-id="093bbda9-cb7b-4053-b9d1-37b5160126d1" data-message-model-slug="gpt-4o" dir="auto"> <p data-end="1155" data-is-last-node="" data-is-only-node="" data-start="339">At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this <i>AudioAbstract</i>.</p> </div> </div> </article>